##  Genomics England Limited - Board Meeting

## Minutes of Meeting held on 14 November 2017 at

## QMUL, Charterhouse Square, London, EC1M 6BQ

|  |  |
| --- | --- |
| Present:  | Sir John Chisholm (Chair) (JC) |
|  | Prof Mark Caulfield (MC) |
|  | Prof Sir John Bell (JB) |
|  | Prof Ewan Birney (EB) |
|  | Prof Dame Kay Davies (KD) |
|  | Sir Malcolm Grant (MG) |
|  | Andy McKinlay (AM) |
|  | Prof Michael Parker (MP) |
|  | Jon Symonds (JS) |
|  | Nick Maltby (NM) |
|  |  |
| In attendance: | Peter Counter (PC) |
|  | Augusto Rendon (AR) |
|  | Graham Colbert (GC) |
|  | Joanne Hackett (JH) |
|  | Mark Bale (MB) |
|  | Sue Hill (SH) |
|  |  |
| Apologies: | Dame Sally Davies (SD) |
|  |  |

**17-18/061 – Apologies:** See above.

**17-18/062 – Chair’s Introduction, update on CEO and new NEDs:** JC welcomed directors to the meeting and declared the meeting quorate.

JC updated the Board on the two new Non-Executive Directors, Keith Stewart and Sir Ron Kerr. The Nomination Committee had approved both appointments and the Board was invited to do the same although it was noted that approval was a reserved matter. **The Board resolved to approve the appointment of the Keith Stewart and Sir Ron Kerr.**

JC also updated the Board on the recruitment of John Mattick as the CEO. The target date for his start is end of Q1 2018. **The Board resolved to approve in principle the appointment of John Mattick as CEO of Genomics England.**

**17-18/063 – Declarations of Conflicts of Interest:** JC reminded the Board that all conflicts needed to be declared. It was noted that the Register was being updated and all directors were asked to respond.

**17-18/064 – Approval of the Minutes of the September Board Meeting and Actions Arising**

The minutes of the September Board Meeting were approved. The Company Secretary was authorised sign the minutes as a true record of the meeting. There were no outstanding actions from the previous meeting.

**17-18/065– Executive Chair’s Report (JC):**

* JC confirmed that the meeting would focus on [confidential – redacted] the bioinformatics pipeline and the commercial strategy if time allowed. All other reports would be taken as read**.**

**17-18/066 – [Confidential item]:**

* [Redacted]

**17-18/067 – [Confidential item]**

* [Redacted]

**17-18/068 – NHS England Report on GMC Activity (GC):** there was no discussion of the NHS England Report.

**17-18/069 Pipeline Report and Dashboard (GC):** there was no discussion of the Pipeline Report and Dashboard report.

**17-18/070 CIO Report (PC):** there was no discussion of the CIO Report.

**17-18/071 - Science, Ethics and GeCIP Report (MC):** there was no discussion of the Science Report.

**17-18/072 - Bioinformatics Report (AR):** there was no discussion of the bioinformatics report.

**17-18/073 – Commercial Report (JH):** there was no discussion of the commercial report. With regard to the slide pack it was agreed that the strategy briefly described (and in more detail in the pack) should be pursued and progress against it should be continued.

**17-18/074 - Communications Report (GC):** there was no discussion of the communications report.

**17-18/075 - Board Committees**: there was no discussion of Board Committees.

**17-18/076 - Any Other Business:** There was no other business.

**17-18/077 - Date, Time and Agenda for Next Meeting**

**IT WAS NOTED that the next Board meeting would be held on 16 January 2018 between 12.30 – 14.30 at Genomics England in Carthusian Street.**

**Close: The meeting closed at 1705**.

…………………………………………………. ……………………………………………………..

Signed Dated